Pfizer Inc. (NYSE:PFE) Shares Acquired by Callan Capital LLC

Callan Capital LLC raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 8.8% in the 4th quarter, HoldingsChannel.com reports. The fund owned 11,576 shares of the biopharmaceutical company’s stock after buying an additional 932 shares during the quarter. Callan Capital LLC’s holdings in Pfizer were worth $333,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Adage Capital Partners GP L.L.C. increased its holdings in shares of Pfizer by 40.5% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after purchasing an additional 1,365,295 shares in the last quarter. LifePlan Financial LLC purchased a new position in shares of Pfizer during the 4th quarter valued at approximately $255,000. Brookstone Capital Management increased its holdings in shares of Pfizer by 88.5% during the 3rd quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock valued at $14,109,000 after purchasing an additional 212,369 shares in the last quarter. ETF Store Inc. increased its holdings in Pfizer by 12.0% in the 3rd quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock worth $214,000 after acquiring an additional 727 shares in the last quarter. Finally, KLCM Advisors Inc. increased its holdings in Pfizer by 75.0% in the 4th quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock worth $5,004,000 after acquiring an additional 74,487 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PFE has been the subject of several recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a report on Thursday, January 4th. Finally, Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Eleven investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $36.33.

Pfizer Trading Up 0.5 %

NYSE PFE traded up $0.12 during trading hours on Friday, reaching $25.38. The company had a trading volume of 46,479,102 shares, compared to its average volume of 42,011,723. The stock has a 50-day moving average of $26.96 and a 200 day moving average of $28.42. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $40.37. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $143.72 billion, a P/E ratio of 70.50, a price-to-earnings-growth ratio of 1.18 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business’s revenue for the quarter was down 41.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.14 earnings per share. As a group, research analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 6.62%. Pfizer’s dividend payout ratio is currently 466.67%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.